SHANGHAI – Two-year-old Engine Biosciences Pte Ltd., a startup with an artificial intelligence (AI) platform approach to drug discovery, recently received a $10 million endorsement from Chinese and U.S. investors. Engine is one of a growing number of AI-first, data-driven biotechs that are plying the latest advances in machine learning to the complex task of understanding human biology to find new medicines.
SHANGHAI – Beijing's Canbridge Life Sciences Inc. has acquired the greater China rights to Puma Biotechnology Inc.'s Nerlynx (neratinib) as an adjuvant for early stage HER2-positive breast cancer and other HER2 tumors, such as gastric cancer, which is highly prevalent in China.
SHANGHAI – Beijing's Canbridge Life Sciences Inc. has acquired the greater China rights to Puma Biotechnology Inc.'s Nerlynx (neratinib) as an adjuvant for early stage HER2-positive breast cancer and other HER2 tumors, such as gastric cancer, which is highly prevalent in China.
SHANGHAI – EOC Pharmaceutical Group, a specialty pharma with seven cancer assets in its pipeline, has started with the end in mind – not just getting its drugs approved by the CFDA but having them be commercially successful as well.
SHANGHAI – EOC Pharmaceutical Group, a specialty pharma with seven cancer assets in its pipeline, has started with the end in mind – not just getting its drugs approved by the CFDA but having them be commercially successful as well.
SHANGHAI – Beigene Ltd. nabbed the Asia-Pacific rights to sitravatinib from Mirati Therapeutics Inc. in a $10 million cash deal, valued at $123 million when additional milestones roll in. The Beijing-based firm also recently closed a public offering of about $800 million to support its growing immuno-oncology pipeline.
SHANGHAI – Beigene Ltd. nabbed the Asia-Pacific rights to sitravatinib from Mirati Therapeutics Inc. in a $10 million cash deal, valued at $123 million when additional milestones roll in. The Beijing-based firm also just announced a $750 million public offering to support its growing immuno-oncology pipeline.
SHANGHAI – Jiangsu Hengrui Medicine Co., of Shanghai and Lianyungang, continues to find success licensing-out the global rights to U.S. biopharmas from its pipeline of 21 new molecular entities.
SHANGHAI – The CFDA recently released "Guiding Principles for the Research and Evaluation of Cell Therapy Products" for trial implementation. This hotly anticipated move now adds cell therapies such as stem cells and chimeric antigen receptor (CAR T) therapies under the umbrella of CFDA reforms that are aligning China's drug regulations with global drug markets.
SHANGHAI – Xinogen (Hong Kong) Pharma Co. Ltd., a subsidiary of Beijing Shenogen Pharmaceuticals Group, has negotiated a deal with Angiochem Inc., of Montreal, to develop and sell ANG-1005, a paclitaxel-peptide drug conjugate for the treatment of leptomeningeal carcinomatosis from breast cancer. The deal gives Xinogen rights for greater China.
